keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer luminal b

keyword
https://www.readbyqxmd.com/read/28211079/gata3-expression-in-triple-negative-breast-cancers
#1
David J Byrne, Siddhartha Deb, Elena A Takano, Stephen B Fox
AIMS: GATA-binding protein 3 (GATA3) is a well-studied transcription factor found to be essential in the development of luminal breast epithelium and has been identified in a variety of tumour types including breast and urotheilial carcinomas making it a useful immunohistochemistry marker in the diagnosis of both primary and metastatic disease. METHODS AND RESULTS: We investigated GATA3 protein expression in a 106 primary triple negative breast carcinomas (100 basal-like, 6 non-basal-like) using Cell Marque mouse monoclonal anti-GATA3 (L50-823)...
February 17, 2017: Histopathology
https://www.readbyqxmd.com/read/28208987/bcl6-mrna-expression-level-in-invasive-duct-carcinoma-not-otherwise-specified
#2
Eman Badr, Eman Masoud, Asmaa Gaber Abdou, Marwa Serag Eldien
INTRODUCTION: B-Cell Lymphoma 6 (BCL6) has an oncogenic role in tumourigenesis of various malignancies. It represses genes involved in terminal differentiation and plays complementary role with Signal Transducer and Activator of Transcription 3 (STAT3) in triple-negative breast cancer cellular function. AIM: To evaluate the expression of BCL6 in cancer breast and determine its correlation with the clinico-pathological features including the molecular subtype of breast carcinoma...
December 2016: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28205042/screening-relevant-age-threshold-of-70%C3%A2-years-and-older-is-a-stronger-determinant-for-the-choice-of-adjuvant-treatment-in-breast-cancer-patients-than-tumor-biology
#3
E C Inwald, O Ortmann, M Koller, F Zeman, F Hofstädter, M Evert, G Brockhoff, M Klinkhammer-Schalke
PURPOSE: The 70-year threshold determines whether patients are eligible or not for the breast cancer screening program in Germany. It is not known whether this age threshold also influences the choice of adjuvant treatment and ultimate outcome. METHODS: 3463 patients were analyzed from the clinical cancer registry Regensburg (Germany) with primary, non-metastatic invasive breast cancer diagnosed between 2000 and 2012. The distribution of tumor biological subtypes was evaluated in breast cancer patients both in those eligible for screening (ESG, 50-69 years) and those not eligible for screening (NESG, ≥70 years)...
February 15, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28195084/calretinin-expression-as-a-reliable-prognostic-marker-in-different-molecular-subtypes-of-breast-carcinoma
#4
Mayada Saad Farrag, Amro Awad El-Karef, Maha Mohammed Amin, Nagwa Mokhtar Helal, Omar Farouk Ali, Nesrine Saad Farrag
BACKGROUND: Calretinin (CR), a known mesothelial marker, is expressed in both epithelial and mesenchymal malignancies including breast cancer. AIMS: We aimed to measure the frequency of CR expression in correlation with other clinicopathological parameters of different molecular subtypes of invasive breast carcinoma and to study its prognostic implications in this common cancer. STUDY DESIGN: Tissue microarrays were constructed from 225 tissue samples of breast carcinoma cases...
January 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/28192598/overall-survival-and-the-response-to-radiotherapy-among-molecular-subtypes-of-breast-cancer-brain-metastases-treated-with-targeted-therapies
#5
Jacob A Miller, Rupesh Kotecha, Manmeet S Ahluwalia, Alireza M Mohammadi, Samuel T Chao, Gene H Barnett, Erin S Murphy, Michael A Vogelbaum, Lilyana Angelov, David M Peereboom, John H Suh
BACKGROUND: The current study was conducted to investigate survival and the response to radiotherapy among patients with molecular subtypes of breast cancer brain metastases treated with or without targeted therapies. METHODS: Patients diagnosed with breast cancer brain metastases at a single tertiary care institution were included. The primary outcome was overall survival, whereas secondary outcomes included the cumulative incidences of distant intracranial failure, local failure, and radiation necrosis...
February 13, 2017: Cancer
https://www.readbyqxmd.com/read/28187434/interface-between-breast-cancer-cells-and-the-tumor-microenvironment-using-platelet-rich-plasma-to-promote-tumor-angiogenesis-influence-of-platelets-and-fibrin-bundles-on-the-behavior-of-breast-tumor-cells
#6
Sheila Siqueira Andrade, Joana Tomomi Sumikawa, Eloísa Dognani Castro, Fabricio Pereira Batista, Edgar Paredes-Gamero, Lilian Carolina Oliveira, Izabel Monastério Guerra, Giovani Bravin Peres, Renan Pelluzzi Cavalheiro, Luiz Juliano, Afonso Pinto Nazário, Gil Facina, Siu Mui Tsai, Maria Luiza Vilela Oliva, Manoel João Batista Castello Girão
Cancer progression is associated with an evolving tissue interface of direct epithelial-tumor microenvironment interactions. In biopsies of human breast tumors, extensive alterations in molecular pathways are correlated with cancer staging on both sides of the tumor-stroma interface. These interactions provide a pivotal paracrine signaling to induce malignant phenotype transition, the epithelial-mesenchymal transition (EMT). We explored how the direct contact between platelets-fibrin bundles primes metastasis using platelet-rich plasma (PRP) as a source of growth factors and mimics the provisional fibrin matrix between actively growing breast cancer cells and the tumor stroma...
February 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28183251/the-real-impact-of-target-therapy-in-breast-cancer-patients-between-hope-and-reality
#7
Sebastiano Bordonaro, Massimiliano Berretta, Antonino Carmelo Tralongo, Silvia Clementi, Brigida Stanzione, Paolo Tralongo
Over the last 15 years, we have seen a huge expansion of the development of drugs directed against biomolecular targets within breast cancer cells. The over-expression of certain receptors (ER, PgR, HER-2, VEGF-R), as well as alteration of several intracellular signal transduction pathways (the PI3K-AKT-mTOR pathway, MEK-MAPK pathway, loss of PTEN, etc ...) have a great impact on the likelihood of recurrence and progression of the disease, influencing the natural history of breast cancer. The recent biomolecular classification of breast cancer (Luminal A / B, HER2-driven, Basal Like) allowed finally to identify specific treatments against molecular target to associate or not to traditional chemotherapy, and to use in relation to the prognosis of the disease...
February 8, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28178676/lymph-node-status-in-different-molecular-subtype-of-breast-cancer-triple-negative-tumours-are-more-likely-lymph-node-negative
#8
Ning Liu, Zhigang Yang, Xiaozhen Liu, Yun Niu
BACKGROUND AND OBJECTIVES: To investigate the association between different molecular subtype(MST) and the axillary lymph nodal(ALN) status. METHODS: A total of 528 female patients with primary breast cancer were collected. Survival estimates were calculated using the Kaplan-Meier method, univariate and multivariate logistic regression models. RESULTS: Triple negative and Luminal A breast cancers were more frequently node-negative(N0) when compared to Luminal B and Her-2 positive cancers (77...
February 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28177554/identifying-relations-between-imaging-phenotypes-and-molecular-subtypes-of-breast-cancer-model-discovery-and-external-validation
#9
Jia Wu, Xiaoli Sun, Jeff Wang, Yi Cui, Fumi Kato, Hiroki Shirato, Debra M Ikeda, Ruijiang Li
PURPOSE: To determine whether dynamic contrast enhancement magnetic resonance imaging (DCE-MRI) characteristics of the breast tumor and background parenchyma can distinguish molecular subtypes (ie, luminal A/B or basal) of breast cancer. MATERIALS AND METHODS: In all, 84 patients from one institution and 126 patients from The Cancer Genome Atlas (TCGA) were used for discovery and external validation, respectively. Thirty-five quantitative image features were extracted from DCE-MRI (1...
February 8, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/28169235/prediction-of-heterogeneity-in-breast-cancer-immunophenotype-at-ductal-carcinoma-in-situ-stage
#10
Manish Rohilla, Amanjit Bal, Gurpreet Singh, Kusum Joshi
INTRODUCTION: Ductal carcinoma in situ (DCIS) is considered a heterogeneous lesion at the molecular level. However, there is a paucity of literature about the existence of molecular subtypes in DCIS which can predict their biological behavior at the preinvasive stage. MATERIALS AND METHODS: Precise prevalence of molecular subtypes of pure DCIS and DCIS component of infiltrating duct carcinoma (IDC) was evaluated using immunohistochemistry and correlated with known prognostic factors...
October 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28167613/epigenomic-inactivation-of-rasgaps-activates-ras-signaling-in-a-subset-of-luminal-b-breast-cancers
#11
Rosalie Sears, Joe W Gray
Invasion and metastasis of a subset of aggressive luminal B breast cancers is driven by the concomitant inactivation of the RasGAPs DAB2IP and RASAL2. Inactivation of both proteins increases RAS activity and drives invasion, whereas inactivation of DAB2IP specifically promotes NF-κB-mediated epithelial-mesenchymal transition. Cancer Discov; 7(2); 131-3. ©2017 AACRSee related article by Olsen et al., p. 202.
February 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28166261/radiomic-analysis-reveals-dce-mri-features-for-prediction-of-molecular-subtypes-of-breast-cancer
#12
Ming Fan, Hui Li, Shijian Wang, Bin Zheng, Juan Zhang, Lihua Li
The purpose of this study was to investigate the role of features derived from breast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and to incorporated clinical information to predict the molecular subtypes of breast cancer. In particular, 60 breast cancers with the following four molecular subtypes were analyzed: luminal A, luminal B, human epidermal growth factor receptor-2 (HER2)-over-expressing and basal-like. The breast region was segmented and the suspicious tumor was depicted on sequentially scanned MR images from each case...
2017: PloS One
https://www.readbyqxmd.com/read/28154782/ki-67-as-a-prognostic-marker-according-to-breast-cancer-molecular-subtype
#13
Nahed A Soliman, Shaimaa M Yussif
OBJECTIVE: Ki-67 plays an important function in cell division, but its exact role is still unknown. Moreover, few works regarding its overall function were published. The present study evaluated the clinical significance of Ki-67 index as a prognostic marker and predictor of recurrence in different molecular subtypes of breast cancer. The relationship of Ki-67 index with different clinicopathological factors was also analyzed. METHODS: Ki-67 index was measured in 107 cases of primary breast cancer from 2010-2012...
December 2016: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/28143493/the-yin-yan-of-ccl2-a-minor-role-in-neutrophil-anti-tumor-activity-in-vitro-but-a-major-role-on-the-outgrowth-of-metastatic-breast-cancer-lesions-in-the-lung-in-vivo
#14
Nicole Lavender, Jinming Yang, Sheau-Chiann Chen, Jiqing Sai, C Andrew Johnson, Philip Owens, Gregory D Ayers, Ann Richmond
BACKGROUND: The role of the chemokine CCL2 in breast cancer is controversial. While CCL2 recruits and activates pro-tumor macrophages, it is also reported to enhance neutrophil-mediated anti-tumor activity. Moreover, loss of CCL2 in early development enhances breast cancer progression. METHODS: To clarify these conflicting findings, we examined the ability of CCL2 to alter naïve and tumor entrained neutrophil production of ROS, release of granzyme-B, and killing of tumor cells in multiple mouse models of breast cancer...
January 31, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28141868/progressive-apobec3b-mrna-expression-in-distant-breast-cancer-metastases
#15
Anieta M Sieuwerts, Willemijne A M E Schrijver, Simone U Dalm, Vanja de Weerd, Cathy B Moelans, Natalie Ter Hoeve, Paul J van Diest, John W M Martens, Carolien H M van Deurzen
BACKGROUND: APOBEC3B was recently identified as a gain-of-function enzymatic source of mutagenesis, which may offer novel therapeutic options with molecules that specifically target this enzyme. In primary breast cancer, APOBEC3B mRNA is deregulated in a substantial proportion of cases and its expression is associated with poor prognosis. However, its expression in breast cancer metastases, which are the main causes of breast cancer-related death, remained to be elucidated. PATIENTS AND METHODS: RNA was isolated from 55 primary breast cancers and paired metastases, including regional lymph node (N = 20) and distant metastases (N = 35)...
2017: PloS One
https://www.readbyqxmd.com/read/28140614/preoperative-mri-evaluation-of-axillary-lymph-nodes-in-invasive-ductal-carcinoma-comparison-of-luminal-a-versus-luminal-b-subtypes-in-a-paradigm-using-ki-67-and-receptor-status
#16
Michael J Plaza, Priyanka Handa, Lisa E Esserman
OBJECTIVE: The purpose of this study is to assess whether luminal A versus luminal B molecular subtypes of breast cancer affect the diagnostic utility of preoperative MRI evaluation of the axilla. MATERIALS AND METHODS: This study identified 125 patients who underwent preoperative breast MRI evaluation of tumors classifiable as luminal A or luminal B molecular subtypes between January 2012 and August 2014. The subtypes were classified on the basis of immunohistochemical staining surrogates combining receptor status and the Ki-67 proliferation index...
January 31, 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28138856/the-impact-of-reexcision-and-residual-disease-on-local-recurrence-following-breast-conserving-therapy
#17
Stephen A Mihalcik, Bhupendra Rawal, Lior Z Braunstein, Alex Capuco, Julia S Wong, Rinaa S Punglia, Jennifer R Bellon, Jay R Harris
PURPOSE: Risk factors for local recurrence (LR) following breast-conserving therapy (BCT) inform the need for local therapy. A Danish population-based cohort study identified residual disease on reexcision as an independent risk factor for LR but was limited by incomplete data on biologic subtype (Bodilsen et al. 2015 in Ann Surg Oncol 22: S476-S485). We sought to elaborate this risk in an independent cohort with clearly defined biologic subtypes. METHODS: The study population included patients with localized invasive breast cancer with complete biologic subtype data treated with BCT with one or zero reexcisions at one institution from 1998 to 2008...
January 30, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28133282/-pathological-complete-response-obtained-by-eribulin-chemotherapy-in-a-case-of-advanced-breast-cancer
#18
Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, Koji Takada, Tamami Morisaki, Tsutomu Takashima, Satoru Noda, Naoyoshi Onoda, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
A goal for treating advanced disease is prolonging survival while maintaining a good quality of life(QOL). Eribulin chemotherapy may be suitable for this purpose. We report a case of advanced breast cancer with pathological complete response (pCR)obtained by eribulin chemotherapy. The patient was a 43-year-old woman who complained of a right mammary mass. A tumor measuring approximately 3 cm was palpated, and breast cancer was detected via ultrasound examination. Core needle biopsy indicated invasive ductal carcinoma based on histopathological findings...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28133011/-evaluation-of-bevacizumab-in-combination-with-weekly-paclitaxel-for-locally-advanced-breast-cancer
#19
Hitoshi Sugimoto, Fukuichiro Orita, Yuichiro Kume, Hironobu Baba, Yuya Sato, Naoaki Hoshino, Yoshinobu Nishioka
Locally advanced breast cancer that exhibits bleeding, has a foul odor, and expresses an exudate often reduces the quality of life(QOL). Bevacizumab(Bv)in combination with weekly paclitaxel(PTX)therapy has a high response rate. To date, we have used this combination for 8 cases of locally advanced breast cancer in our hospital. The patients' mean age was 62.1 years. The tumors were T4b in 6 cases, T4c in 1 case and T4d in 1 case. The clinical stage was Stage III B in 1 case and Stage IV in 7 cases. The subtype was Luminal A in 2 cases, Luminal B in 4 cases, and triple negative in 2 cases...
November 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28124996/expression-of-lipid-metabolism-related-proteins-differs-between-invasive-lobular-carcinoma-and-invasive-ductal-carcinoma
#20
Yoon Jin Cha, Hye Min Kim, Ja Seung Koo
We comparatively investigated the expression and clinical implications of lipid metabolism-related proteins in invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) of the breast. A total of 584 breast cancers (108 ILC and 476 IDC) were subjected to tissue microarray and immunohistochemical analysis for lipid metabolism-related proteins including hormone-sensitive lipase (HSL), perilipin A, fatty acid binding protein (FABP)4, carnitine palmitoyltransferase (CPT)-1, acyl-CoA oxidase 1, and fatty acid synthetase (FASN)...
January 23, 2017: International Journal of Molecular Sciences
keyword
keyword
93454
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"